Merck and Co Inc (MRK): Keytruda misses phase-3 primary endpoint...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	829
Posts	119592
Boards Moderated	14
Alias Born	09/05/2002

DewDiligence

Re: None

Tuesday, 06/09/2020 5:26:26 PM

Tuesday, June 09, 2020 5:26:26 PM

Keytruda misses phase-3 primary endpoint in bladder cancer (KEYNOTE-361 study):

https://www.businesswire.com/news/home/20200609005739/en

Merck…today announced that the Phase 3 KEYNOTE-361 trial evaluating KEYTRUDA…in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (bladder cancer) did not meet its pre-specified dual primary endpoints of overall survival (OS) or progression-free survival (PFS), compared with standard of care chemotherapy.

…The monotherapy arm of the study [i.e. Keytruda compared to standard chemotherapy] was not formally tested, since superiority was not reached for OS or PFS in the KEYTRUDA combination arm.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”